||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Allergy Therapeutics Share Discussion Threads
Showing 3251 to 3274 of 3275 messages
|From elsewhere on the web
Allergy Therapeutics plc 198.6% Potential Upside Indicated by Panmure Gordon
by: Amilia Stone 26th September 2016
Allergy Therapeutics plc using EPIC/TICKER code LON:AGY has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Panmure Gordon. Allergy Therapeutics plc are listed in the Health Care sector within AIM. Panmure Gordon have set their target price at 53 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 198.6% from today’s opening price of 17.75 GBX. Over the last 30 and 90 trading days the company share price has decreased 1.35 points and decreased 1.3 points respectively.
Allergy Therapeutics plc LON:AGY has a 50 day moving average of 19.03 GBX and a 200 day moving average of GBX. The 1 year high for the stock price is 34.82 GBX while the 52 week low for the stock is 17.29 GBX. There are currently 601,432,778 shares in issue with the average daily volume traded being 252,540. Market capitalisation for LON:AGY is £106,934,752 GBP.
Allergy Therapeutics plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company’s business segments are Central Europe, Southern Europe, the United Kingdom and Rest of World.|
|Proactive Investors is here: http://tinyurl.com/jrbgy5s|
|Perfect news this morning and that should act as the stimulus we need.
This may help too..........From another board.
"Allergy Therapeutics trading at a significant discount: buy
Allergy Therapeutics (AGY) is trading at a discount to peers and additional upside is in the pipeline.
Numis analyst Paul Cuddon retained his ‘buy’ recommendation and target price of 37p on the shares, which fell 5.4% to 17.4p yesterday.
‘Revenue growth of 19% on constant currency reflects Allergy Therapeutics’ strong performance in Europe, and in our opinion more than compensates for the setback in US development,’ he said.
‘We continue to see a strong outlook for the business in Europe and following the disappointing commercial performance of daily tables in the US, ultimately see it as the best-placed company to crack the larger US market, with a treatment format that suits the US allergists’ preference for injections.
‘The shares trade at a material discount to peers with significant additional upside from the pipeline, which now includes a promising peanut vaccine.’ "|
|Allergy Therapeutics CEO Manuel Llobet will be presenting to investors at the Proactive One2One Healthcare investor forum on the 6th October in Mayfair. For further details and registration please click here: http://tinyurl.com/j7mz7r7|
|Morning - new films for Allergy. Results film and re-edited Overview film
|I have been traveling all day but see another fall in the price. May I ask if the 17.38 were in fact Buy trades and not a reported sell trades? Any update appreciated.
AGY have certainly got some people they have upset judging by the sheer volume of shares that have materialised - a holdings notice coming?
Nice one Manuel buying a hundred k
The are two lots of two words that will change everything here impo.
The first pair are PROGRESS /USA and the second pair are SUCCESS/USA.
My money certainly looks safe tonight but the Cadillac et al will have wait until they RNS those two words.
|Well these results are a bit better than I expected. They have a solid financial platform on which to pursue the US opportunity. Hopefully this may spark some recovery in the share price but it being AIM you never know!|
|Well I had a small top-up ahead of Monday. Not expecting any fireworks just some solid numbers for Europe and reassurance that the US opportunity for grass allergy is still huge despite the delay. Would be good to get some further insight in to the peanut opportunity.|
|I thought that, as I know that they are presenting on the 6th of October and they wouldn't do that in front of this large and high profile audience if they didn't have something to say.
I plan to attend that and then decide even if I have to pay more.
I too am surprised at the flatness|
|All flat pre-results. I'm thinking I may have a little top-up today....|
|Overhang now being cleared ahead of Monday????
We will see if we get a tick.
|Just how much 'hang' is in an overhang?|
|Am I alone in being amazed at the constant support for AGY with over 100 buy trades in the last week or so and no movement.
Whatever volume was dropped it must have been significant.
Nice to see the level of confidence and with euro/pound where it is. It is no wonder!
|My failure comment was a question. The only failure in a long time here is the mega important dose trialling. The one that truly mattered.
Of course they can right the ship with multiple lines of opportunity in their portfolio but they need to be seen to deliver them.
I shall most likely attend that meeting in London on October 6th.
HOLD for me at the moment as the risks here are currently balanced with opportunity.....just.
|A bit of institutional off-loading. I think AGY are a million miles away from failure. Biology has a habit of being unpredictable. Your previous post from email correspondence with Manuel was, in my view, reassuring with respect to the issue of dose selection. Things will take longer but so be it. In the meantime they are profitable in Europe and continue to grow market share. And best of all they are investing in other opportunities with peanut allergy. At 18p they are very cheap when balanced against their future business aspirations. I will continue to add on that basis and hope that one day I can retire early on the proceeds! If that doesn't happen then I will have to hope my RBS share holding comes good.....fat chance of that!|
|That is some overhang that they are shifting.!!! Another 750,000 through tonight.
Are there more still to come - is it the price of failure?|
It looks to me as if we have had a million sell shares moved through the market and what a great job the mm's did. I suppose that IC rec was manner from heaven for them.
Did someone get pretty hacked off that a company as safe as AGY could fail on the dosing trial.
I would be interested to know just how much that failure costs us and how much another trial will cost.
Thankfully the base business is doing well enough to carry that very upsetting news and the pound is in the right area now for them.
|Nice one Maddox, I couldn't get to this last year but will make an effort.|
I've just spotted that AGY are presenting at Proactive Investors One2One Investor Forum in London:
Allergy Therapeutics plc | Cello Group plc | Sphere Medical Holding PLC | ValiRx Plc
Oct 6th 2016, 6.00 pm - Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair
It's free to attend and I've booked my place. It's the opportunity to talk to the management that I really appreciate.
|I figure that we had a large overhang which went through yesterday and cleared this morning. They dropped the bid while they cleared the last of the overhang.
|Unless they are sells? Think of it as a buying opportunity!|
|Can any of our regulars (or anyone else)offer a view as to what on earth is going on here? Hundreds of thousands bought Friday and To-day and then 'kerplunk' they drop the price!|
Thank you. I thought it was something like that.|
|Buy recommendation in IC today.|